Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells

Journal of Pharmaceutical Analysis(2021)10.1016/j.jpha.2021.06.002Source: DataRank Database

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells is a research paper published in Journal of Pharmaceutical Analysis (2021). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.47)OA: goldTopics (25)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Elizabeth Mazzio,Sunil Kumar Surapaneni ORCID,Shallu Kutlehria ORCID,Arindam Mondal ORCID,Ramesh Badisa

Live enrichment

PubMed:35028186 OpenAlex:https://openalex.org/W3176773542

NSF

Grant: 1735968

National Institutes of Health

Grant: U54 MD007582

National Institutes of Health

Grant: 5U54MD007582-37

FAMU Center for Health Disparities Research

BLRD VA

Grant: I01 BX004931

BLRD VA

Grant: IK6 BX004015

FWCI

0.47

Citation Percentile

0.5%

Citation Trend

2022

2023

2024

2025

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jpha.2021.06.002

publisherhttps://doi.org/10.1016/j.jpha.2021.06.002

publisherhttps://api.elsevier.com/content/article/PII:S2095177921000629?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2095177921000629?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35028186

Fields of Study

Cancer, Hypoxia, and MetabolismGinseng Biological Effects and ApplicationsPharmacological Effects of Natural Compounds0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

ErlotinibChemistryDownregulation and upregulationCancer researchEpidermal growth factor receptorTranscriptomeGefitinibMolecular biologyBiochemistryGene expressionGeneReceptorBiologyDrug resistanceOriginal ArticleTherapeutics. PharmacologyRM1-950Combination therapyTranscriptomic analysis

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being